The 7 major posterior uveitis markets reached a value of USD 438.5 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 723.4 Million by 2035, exhibiting a growth rate (CAGR) of 4.68% during 2025-2035.
Report Attribute
|
Key Statistics
|
---|---|
Base Year | 2024 |
Forecast Years | 2025-2035 |
Historical Years |
2019-2024
|
Market Size in 2024
|
USD 438.5 Million |
Market Forecast in 2035
|
USD 723.4 Million |
Market Growth Rate 2025-2035
|
14.62% |
The posterior uveitis market has been comprehensively analyzed in IMARC's new report titled "Posterior Uveitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Posterior uveitis is a vision-threatening inflammatory disease that occurs in the posterior segment of the eye, comprising the choroid, retina, and optic nerve. It is a multifaceted and heterogeneous condition that can be caused by infectious etiologies like toxoplasmosis, cytomegalovirus, tuberculosis, and syphilis or by non-infectious autoimmune diseases like sarcoidosis, Behçet's disease, and multiple sclerosis. If left untreated, the disease can result in severe vision impairment, thus necessitating early diagnosis and early treatment. Clinical features of posterior uveitis include blurred vision, floaters, pain, photophobia, and, in the advanced form, irreversible loss of vision. Given its multi-factorial etiology, the diagnosis involves the integration of clinical assessment, fundoscopy, optical coherence tomography (OCT), fluorescein angiography, and laboratory investigations to establish underlying etiologies. Since it is long-standing and chronic in nature, posterior uveitis needs extended management protocols so that complications are avoided, namely retinal detachment, macular edema, and optic neuropathy, focusing on the role of good-treatment modalities.
The increasing incidence of infectious and non-infectious posterior uveitis is one of the key drivers for the growth of the market. Autoimmune disorders such as Behçet's disease, sarcoidosis, multiple sclerosis, and Vogt-Koyanagi-Harada syndrome are strong drivers for the prevalence of disease, for which long-term immunosuppressive therapy is needed. Infectious causes such as cytomegalovirus, toxoplasmosis, tuberculosis, and syphilis have also been implicated with posterior uveitis, requiring antimicrobial or antiviral therapy. Increasing worldwide burden of disease of these conditions, as well as aging population demography and growing awareness of ocular disease, further drives marketplace demand. Entry of biologic agents, e.g., TNF inhibitors adalimumab and infliximab and IL blockers, has significantly accelerated disease treatment via targeted therapy with less systemic adverse effects compared with conventional corticosteroids and immunosuppressants. Moreover, advancements in sustained-release intravitreal implants such as fluocinolone acetonide and dexamethasone provide prolonged inflammatory control with a reduced requirement of frequent dosing and optimal patient compliance. Another trend affecting market dynamics is the growing preference towards local corticosteroid injections as opposed to systemic therapy due to lower systemic side effects and improved treatment efficacy in localized inflammation.
IMARC Group's new report provides an exhaustive analysis of the posterior uveitis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the posterior uveitis market in any manner.
Humira (adalimumab) is an FDA-approved biologic agent for treatment of adults with non-infectious intermediate, posterior, and panuveitis. It is a TNF-α antagonist that inhibits tumor necrosis factor-alpha (TNF-α), suppresses inflammation, and manages disease progression. Clinical trials proved that there was significantly less risk of treatment failure than with placebo.
Ozurdex is a biodegradable intravitreal device that releases 0.7 mg of dexamethasone, a corticosteroid, directly to the posterior segment of the eye. It very effectively decreases inflammation due to non-infectious posterior uveitis, enhancing visual acuity and reducing swelling of the retina.
YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg is a small, non-bioerodible implant to treat posterior segment chronic non-infectious uveitis. It releases a continuous, low-dose corticosteroid directly within the eye for 36 months, lowering inflammation and potentially lowering the incidence of flare-ups and treatment sessions.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current posterior uveitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Humira (Adalimumab) | AbbVie/AstraZeneca |
Ozurdex (Dexamethasone Intravitreal Implant) | AbbVie |
Yutiq (Fluocinolone acrtonide intravitral implant) | ANI Pharmaceuticals |
Brepocitinib | Priovant Therapeutics |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Posterior Uveitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies